Maricann Group Inc. (OTCQB: MRRCF) announced on May 30th the company’s financial reports for the first quarter of 2018. The company reported total revenue for Q1 decreased significantly when compared to Q1 of 2017. The company’s reported quarter revenue of approximately $463,112 for Q1 2018 is $418,317 less than 2017’s Q1 revenue total of $881,490.
This significant drop to revenue is attributed to a large transaction that occurred shortly before the closing of Q1. However, the company is already showing early reporting revenue of $697,840 for Q2.
The company’s quarter highlights included an exclusive distribution agreement with a Colorado-based company with award-winning genetics, a third license from Health Canada, a letter of intent to acquire HAXXON AG, and EMA-GMP certification for its cultivation facilities in Ontario.